Association between TYMS gene polymorphism and methotrexate treatment adverse drug reaction a sample of rheumatoid arthritis patients

Abstract

Methotrexate (MTX) is a popular therapy for MTX for several diseases, including RA, owing to its anti-inflammatory and immunomodulatory effects, but its usage is associated with adverse effects. The current study aims to study the possible relationship between thymidylate synthetase (TYMS) gene polymorphism and MTX's adverse drug reaction (ADR). The study involved 95 RA patients; Sanger sequencing polymerase chain reaction was utilized for the TYMS gene region. The MTX ADR had a high rate (88.4%); however, there was no significant association between genetic polymorphism and the incidence of overall ADR. At the same time, some haplotypes carry an increased risk of ADR, like the A₆₅₇₃₃₄C_rs2853741C_rs2606241T_rs2853742haplotype, while others reduce the risk of ADR, like C₆₅₇₃₃₄C_rs2853741C_rs2606241T_rs2853742haplotype, but none of the haplotypes reach statistically significant. In conclusion, there is no association between the genetic polymorphism of the TYMS gene and the development of methotrexate adverse drug reactions.